Compare EVH & SGHT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | EVH | SGHT |
|---|---|---|
| Founded | 2011 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Other Consumer Services | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 272.4M | 235.0M |
| IPO Year | 2015 | 2021 |
| Metric | EVH | SGHT |
|---|---|---|
| Price | $4.00 | $4.97 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 15 | 7 |
| Target Price | $7.93 | ★ $9.08 |
| AVG Volume (30 Days) | ★ 2.6M | 329.2K |
| Earning Date | 05-07-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 28.16 |
| EPS | N/A | N/A |
| Revenue | ★ $907,957,000.00 | $77,363,000.00 |
| Revenue This Year | $33.89 | $11.67 |
| Revenue Next Year | $15.84 | $10.39 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $2.10 | $3.11 |
| 52 Week High | $11.92 | $9.24 |
| Indicator | EVH | SGHT |
|---|---|---|
| Relative Strength Index (RSI) | 61.40 | 58.01 |
| Support Level | $3.68 | $4.86 |
| Resistance Level | $4.32 | $5.25 |
| Average True Range (ATR) | 0.35 | 0.39 |
| MACD | 0.00 | 0.06 |
| Stochastic Oscillator | 49.30 | 60.84 |
Evolent Health Inc is engaged in healthcare delivery and payment. The company supports health systems and physician organizations in their migration toward value-based care and population health management. It provides specialty care management services in oncology, cardiology, musculoskeletal markets and holistic total cost of care management along with an integrated platform for health plan administration and value-based business infrastructure under one go to market package. The solutions provided by the company includes: Oncology, Cardiology, Musculoskeletal, Administrative Services, Advanced Illness, Genetic Testing, Physical Medicine, Radiology, and Surgical Management.
Sight Sciences Inc is an ophthalmic medical device company focused on the development and commercialization of surgical and nonsurgical technologies for the treatment of prevalent eye diseases. The company operates through two segments: Interventional Glaucoma, which generates the majority of revenue and includes the OMNI Surgical System family of products and the SION Surgical Instrument used in minimally invasive glaucoma surgery to reduce intraocular pressure in adult patients with open-angle glaucoma; and Interventional Dry Eye, which includes the TearCare System, an interventional device designed to melt and facilitate the removal of meibomian gland obstructions and restore gland functionality in adult patients with evaporative dry eye disease.